By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Biofortuna said this week it has raised £1 million ($1.6 million), which it will use to develop a market for its diagnostic genotyping products and new products.

The funding is being provided by EV Tech, Catapult Venture Managers, Alliance Fund Managers, and Biofortuna's non-executive directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.